Quality Initiatives MR Imaging in Patients at Risk for Developing Nephrogenic Systemic Fibrosis: Protocols, Practices, and Imaging Techniques to Maximize Patient Safety
- 1 January 2009
- journal article
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 29 (1), 9-22
- https://doi.org/10.1148/rg.291085072
Abstract
Nephrogenic systemic fibrosis (NSF) is a rare but potentially debilitating or even fatal fibrosing condition that most often affects the skin but is now also recognized to involve multiple organs. The first report on NSF was published in 1997, and there is mounting evidence that this condition is associated with renal failure and the administration of large amounts of gadolinium. Although gadolinium-enhanced magnetic resonance (MR) imaging was once considered one of the safer imaging procedures, concerns over NSF have led the radiology community to rethink its imaging practices. Several noncontrast angiographic techniques based on fast spin-echo, gradient-echo, phase-contrast, and inversion-recovery principles are currently available. These techniques allow MR angiography to be performed safely, even in patients at risk for developing NSF. When use of gadolinium-based contrast material is necessary for diagnosis, it is possible to reduce total gadolinium administration through the use of agents with higher relaxivity, time-resolved imaging, high-field-strength magnets, and body compression devices. Management of NSF also requires an understanding of the risk factors of this disease and developing an institutional policy for identifying and testing at-risk patients.Keywords
This publication has 18 references indexed in Scilit:
- Stability of linear and macrocyclic gadolinium based contrast agentsThe British Journal of Radiology, 2007
- MR contrast agents: Physical and pharmacologic basicsJournal of Magnetic Resonance Imaging, 2007
- Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosisJournal of the American Academy of Dermatology, 2007
- A Summary of Safety of Gadofosveset (MS-325) at 0.03 mmol/kg Body Weight DoseInvestigative Radiology, 2006
- Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agentsContrast Media & Molecular Imaging, 2006
- Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedemaJournal of Cutaneous Pathology, 2005
- Dialysis‐associated systemic fibrosis (nephrogenic fibrosing dermopathy): Study of inflammatory cells and transforming growth factor β1 expression in affected skinArthritis & Rheumatism, 2004
- Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease)Journal of the American Academy of Dermatology, 2003
- Imaging of adrenal massesEuropean Journal of Radiology, 2002
- Scleromyxoedema-like cutaneous diseases in renal-dialysis patientsThe Lancet, 2000